GH Guardant Health Inc
Price (delayed)
$43.49
Market cap
$5.37B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.56
Enterprise value
$6.04B
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health
Highlights
The gross profit has grown by 33% YoY and by 8% from the previous quarter
Guardant Health's revenue has increased by 31% YoY and by 7% from the previous quarter
GH's equity has shrunk by 188% YoY and by 132% QoQ
Guardant Health's quick ratio has decreased by 24% YoY and by 15% from the previous quarter
Key stats
What are the main financial stats of GH
Market
Valuations
Earnings
Shares outstanding
123.42M
Market cap
$5.37B
Enterprise value
$6.04B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
7.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.18
Revenue
$739.02M
Gross profit
$449.22M
Operating income
-$443.59M
Net income
-$436.37M
EBIT
-$432.51M
EBITDA
-$390.12M
Free cash flow
-$274.94M
Per share
Balance sheet
Liquidity
EPS
-$3.56
EPS diluted
-$3.56
Free cash flow per share
-$2.24
Book value per share
-$1.13
Revenue per share
$6.02
TBVPS
$12.02
Total assets
$1.49B
Total liabilities
$1.63B
Debt
$1.31B
Equity
-$139.65M
Working capital
$829.53M
Debt to equity
-9.36
Current ratio
4.68
Quick ratio
4.67
Net debt/EBITDA
-1.74
Margins
Efficiency
Dividend
EBITDA margin
-52.8%
Gross margin
60.8%
Net margin
-59%
Operating margin
-60%
Return on assets
-27.5%
Return on equity
N/A
Return on invested capital
-24%
Return on capital employed
-34.3%
Return on sales
-58.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GH stock price
How has the Guardant Health stock price performed over time
Intraday
2.4%
1 week
-5.13%
1 month
2.21%
1 year
109.19%
YTD
42.36%
QTD
2.09%
Financial performance
How have Guardant Health's revenue and profit performed over time
Revenue
$739.02M
Gross profit
$449.22M
Operating income
-$443.59M
Net income
-$436.37M
Gross margin
60.8%
Net margin
-59%
The company's operating margin rose by 40% YoY and by 19% QoQ
The gross profit has grown by 33% YoY and by 8% from the previous quarter
Guardant Health's revenue has increased by 31% YoY and by 7% from the previous quarter
The net margin is up by 31% year-on-year and by 20% since the previous quarter
Growth
What is Guardant Health's growth rate over time
Valuation
What is Guardant Health stock price valuation
P/E
N/A
P/B
N/A
P/S
7.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.18
The EPS is up by 17% since the previous quarter and by 17% year-on-year
GH's equity has shrunk by 188% YoY and by 132% QoQ
The P/S is 63% below the 5-year quarterly average of 18.9 but 50% above the last 4 quarters average of 4.7
Guardant Health's revenue has increased by 31% YoY and by 7% from the previous quarter
Efficiency
How efficient is Guardant Health business performance
The return on sales is up by 31% year-on-year and by 21% since the previous quarter
Guardant Health's ROIC has decreased by 17% YoY but it has increased by 17% from the previous quarter
GH's ROA is up by 11% since the previous quarter
Dividends
What is GH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GH.
Financial health
How did Guardant Health financials performed over time
Guardant Health's total assets is 9% less than its total liabilities
GH's current ratio is down by 28% year-on-year and by 25% since the previous quarter
Guardant Health's quick ratio has decreased by 24% YoY and by 15% from the previous quarter
GH's equity has shrunk by 188% YoY and by 132% QoQ
GH's debt to equity has surged by 57% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.